Healthcare Services

Nodular Prurigo Market Outlook 2026–2035 Driven by Key Growth Factors and Industry Projections

April 3, 2026April 3, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Much Is The Nodular Prurigo Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?

The nodular prurigo market size has shown strong growth in recent years. It is forecast to increase from $1.25 billion in 2025 to $1.33 billion in 2026, reflecting a compound annual growth rate (CAGR) of 6.6%. This historical growth can be ascribed to several factors, including the increasing occurrence of chronic dermatological disorders, the limited efficacy of traditional topical treatments, heightened awareness regarding pruritic skin diseases, the expansion of specialized dermatology clinics, and improved diagnostic detection of nodular prurigo.

The nodular prurigo market is projected to experience substantial expansion over the upcoming years, reaching a valuation of $1.7 billion by 2030, driven by a compound annual growth rate (CAGR) of 6.3%. This anticipated growth during the forecast period is fueled by several factors, including the increasing creation of new biologics and monoclonal antibodies, a heightened emphasis on individualized dermatology care, larger investments in research for inflammatory skin diseases, the broadening of advanced immunotherapy pipelines, and a rising need for solutions that offer long-term itch management. Key trends characterizing this period are the greater adoption of targeted immunomodulatory therapies, an increase in the application of biologic treatments for persistent pruritus, an intensifying focus on managing neuropathic itch, the development of more extensive long-term disease management strategies, and a stronger commitment to patient-focused dermatology care.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24624&type=smp

What Key Drivers Are Influencing The Growth Of The Nodular Prurigo Market?

The nodular prurigo market is projected to grow due to the rising demand for targeted therapies. These therapies are medical treatments designed to specifically target and disrupt molecular pathways involved in disease development and spread. The increasing need for targeted therapies can be attributed to their ability to deliver more precise treatments with fewer side effects, thereby improving patient outcomes and offering alternatives to conventional, less specific approaches. Nodular prurigo itself fosters the development of targeted therapies by presenting a clear unmet medical need tied to specific immune pathways such as IL-4, IL-13, and IL-31, which in turn allows for the use of biologics that precisely block these inflammatory signals for more effective treatment. As an illustration, in January 2024, the American Society of Gene & Cell Therapy, a US-based organization focused on gene and cell therapy, reported that in Q4 2023, the number of gene therapies in Phase III rose by 10% from the preceding quarter, marking its first increase since Q3 2022. Therefore, the heightened demand for targeted therapies is fueling growth in the nodular prurigo market.

What Major Segment Divisions Exist Within The Nodular Prurigo Market?

The nodular prurigo market covered in this report is segmented –

1) By Type: Chronic Nodular Prurigo, Acute Nodular Prurigo, Subacute Nodular Prurigo

2) By Treatment Type: Topical Treatments, Systemic Treatments, Phototherapy, Immunosuppressants

3) By Patient Demographics: Adults, Children, Elderly

4) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) By Chronic Nodular Prurigo: Idiopathic Chronic Nodular Prurigo, Secondary To Dermatologic Conditions, Neuropathic Causes, Systemic Disease-Associated, Psychogenic Prurigo

2) By Acute Nodular Prurigo: Insect Bite-Induced, Allergic Reactions, Drug-Induced Prurigo, Infectious Triggers

3) By Subacute Nodular Prurigo: Healing Phase Of Chronic Prurigo, Post-Inflammatory Prurigo, Transient Dermatoses, Reaction To Environmental Irritants

Which Upcoming Trends Are Expected To Influence The Nodular Prurigo Market?

Companies operating within the nodular prurigo market are directing their efforts toward developing innovative solutions, including anti-IL-31 receptor biologics, to address the growing demand for therapies that modify disease progression. These treatments aim to diminish intense chronic itch, improve the healing of nodules, and reduce reliance on long-term topical corticosteroids and broad immunosuppressants. An anti-IL-31 receptor monoclonal antibody is a biologic therapy that comprises engineered humanized antibodies designed to bind to the IL-31 receptor A on sensory and immune cells, thus blocking IL-31 signaling, which is implicated in chronic pruritus. For example, in August 2024, Galderma S.A., a dermatology pharmaceutical company based in Switzerland, launched Nemluvio (nemolizumab), an advanced anti-IL-31 receptor monoclonal antibody for adults experiencing prurigo nodularis. Nemluvio (nemolizumab) is a humanized monoclonal antibody formulated for subcutaneous injection that attaches to IL-31 receptor A, thereby interrupting itch signaling and subsequent inflammatory pathways; its development focused on alleviating intense chronic itch and promoting the resolution of pruritic nodules, and it is supplied as an autoinjector for use outside of a clinical setting. Noteworthy features include its targeted mechanism, systemic activity beneficial for widespread disease, and a dosing format designed to enhance patient compliance when compared with infusions administered solely in clinics.

Which Companies Are Leading Innovation In The Nodular Prurigo Market?

Major companies operating in the nodular prurigo market are Merck and Co Inc, Sanofi SA, GlaxoSmithKline plc, Amgen Inc, Regeneron Pharmaceuticals Inc, Astellas Pharma Inc, Sun Pharmaceutical Industries Limited, Galderma SA, Incyte Corporation, Kyowa Kirin Co Ltd, LEO Pharma AS, Maruho Co Ltd, Kiniksa Pharmaceuticals Ltd, Keymed Biosciences Co Ltd, Trevi Therapeutics Inc, Menlo Therapeutics Inc, VYNE Therapeutics Inc, Celldex Therapeutics Inc, AbbVie Inc, Pfizer Inc, Novartis AG, Eli Lilly and Company

Read the full nodular prurigo market report here:

https://www.thebusinessresearchcompany.com/report/nodular-prurigo-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Nodular Prurigo Market?

North America was the largest region in the nodular prurigo market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nodular prurigo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Nodular Prurigo Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24624&type=smp

Browse Through More Reports Similar to the Global Nodular Prurigo Market 2026, By The Business Research Company

Neuralgia Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/neuralgia-treatment-global-market-report

Dental Sleep Medicine Global Market Report

https://www.thebusinessresearchcompany.com/report/dental-sleep-medicine-global-market-report

Urea Cycle Disorders Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/urea-cycle-disorders-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795